Breast Cancer Research Foundation
The largest private funder of breast cancer research worldwide, giving annual grants to more than 250 investigators across the field's leading centres.
Founded in 1993 by Evelyn Lauder, the Breast Cancer Research Foundation funds investigators rather than projects, renewing annual grants to established scientists so they can pursue long-term questions in tumour biology, metastasis, prevention, survivorship and treatment. Its portfolio spans the major US and international centres, including Dana-Farber, MSK, the Royal Marsden and Peter Mac, and it co-funds the Translational Breast Cancer Research Consortium and the Evelyn H. Lauder Founder's Fund on metastasis. BCRF-supported researchers have contributed to CDK4/6 inhibitors, PARP inhibitors in BRCA carriers, immunotherapy in triple-negative disease and ctDNA-guided treatment. Funding figures are published in its annual report.
- Investigator grants
- Translational Breast Cancer Research Consortium
- Founder's Fund for metastasis research
- Drug Research Collaborative
Leads Dana-Farber's breast oncology division and many of the trials that moved ADCs and de-escalated therapy into breast cancer care.
Nancy Lin is the leading authority on brain metastases from breast cancer, including the HER2CLIMB tucatinib data in patients with active brain disease.
Ann Partridge led the POSITIVE trial showing women can safely pause hormone therapy to have a baby.
Breast cancer researcher who turned ctDNA into a tool for choosing treatment, leading SERENA-6 and CAPItello-291.
Showed that immune cells inside breast tumours predict outcome, the basis for de-escalating chemotherapy in TNBC.
Pages like this
not linked directly; found by shared links- InstitutionBreast Cancer Trials
Shares Sherene Loi, Peter MacCallum Cancer Centre, PARP inhibitors, HER2-positive breast cancer.
- PersonEvelyn Lauder
Shares Breast Cancer Research Foundation, Memorial Sloan Kettering Cancer Center.
- IdeaWhich patients' blood clones will become leukaemia after treatment?
Shares PARP inhibitors, Dana-Farber Brigham Cancer Center, Memorial Sloan Kettering Cancer Center, Liquid biopsy (ctDNA).
- PersonSarah-Jane Dawson
Shares Peter MacCallum Cancer Centre, Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer.
- InstitutionChampalimaud Foundation – Champalimaud Clinical Centre
Shares Metastasis is understood least and studied last, HER2-positive breast cancer, Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer.
- IdeaEradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells
Shares CDK4/6 inhibitors, Metastasis is understood least and studied last, HR-positive / HER2-negative breast cancer.
- InstitutionSOLTI Cancer Research Group
Shares CDK4/6 inhibitors, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonClifford A. Hudis
Shares Memorial Sloan Kettering Cancer Center, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.